Back to Authors

Rodríguez‐Oroz, María

https://orcid.org/0000-0001-5962-772X

Mayo Clinic

Ikerbasque

Citations 2

Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests
Hoogland, Jeroen , Wanrooij, Lennard L. van , Boel, Judith A., Goldman, Jennifer G. , Stebbins, Glenn T. , Dalrymple‐Alford, John C. , Junqué, Carme , Pedersen, Kenn Freddy , Mollenhauer, Brit , Zabetian, Cyrus P. , Eslinger, Paul J. , Lewis, Simon J.G. , Wu, Ruey‐Meei , Klein, Martin , Rodríguez‐Oroz, María , Cammisuli, Davide Maria , Biundo, Roberta , Bie, Rob M.A. de , Schmand, Ben , Tröster, Alexander I. , Burn, David J. , Filoteo, J. Vincent , Geurtsen, Gert J. , Disease”, on behalf of the IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson, Goldman, Jennifer G , Dalrymple-Alford, John C , Lewis, Simon J G , Zabetian, Cyrus P , de Bie, Rob M A , Geurtsen, Gert J , Junque, Carme , Marras, Connie , Adler, Charles H. , Barone, Paolo , Litvan, Irene , Weintraub, Daniel , Disease”, on behalf of the IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson, Wu, Ruey-Meei

Movement Disorders | September 14, 2018 | Volume: 33 | Issue: 11 | Pages: 1750-1759

10.1002/mds.110 Get It

AbstractBackground: Numerous neuropsychological tests and test versions are used in Parkinson's disease research, but their relative capacity to detect mild cognitive deficits and their comparability across studies are unknown. The objective of this study was to identify neuropsychological tests that consistently detect cognitive decline in PD across studies.Methods: Data from 30 normed neuropsychological tests across 20 international studies in up to 2908 nondemented PD patients were analyzed. A subset of 17 tests was administered to up to 1247 healthy controls. A 2‐step meta‐analytic approach using standardized scores compared performance in PD with normative data.Results: Pooled estimates of the differences between PD and site‐specific healthy controls identified significant cognitive deficits in PD patients on 14 test scores across 5 commonly assessed cognitive domains (attention or working memory, executive, language, memory, and visuospatial abilities), but healthy control performance was statistically above average on 7 of these tests. Analyses based on published norms only, as opposed to direct assessment of healthy controls, showed high between‐study variability that could not be accounted for and led to inconclusive results.Conclusions: Normed neuropsychological tests across multiple cognitive domains consistently detect cognitive deficits in PD when compared with site‐specific healthy control performance, but relative PD performance was significantly affected by the inclusion and type of healthy controls versus the use of published norms only. Additional research is needed to identify a cognitive battery that can be administered in multisite international studies and that is sensitive to cognitive decline, responsive to therapeutic interventions, and superior to individual cognitive tests. © 2018 International Parkinson and Movement Disorder Society
Mild cognitive impairment as a risk factor for Parkinson's disease dementia
Hoogland, Jeroen , Boel, Judith A., Bie, Rob M.A. de , Geskus, Ronald B. , Schmand, Ben , Dalrymple‐Alford, John C. , Goldman, Jennifer G. , Tröster, Alexander I. , Burn, David J. , Geurtsen, Gert J. , Disease”, on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson, Rodríguez‐Oroz, María , Goldman, Jennifer G , Marras, Connie , Adler, Charles H. , Litvan, Irene , Disease”, on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson, Dalrymple-Alford, John C , de Bie, Rob M A , Geurtsen, Gert J

Movement Disorders | June 12, 2017 | Volume: 32 | Issue: 7 | Pages: 1056-1065

10.1002/mds.27002 Get It

ABSTRACT Background The International Parkinson and Movement Disorder Society criteria for mild cognitive impairment in PD were recently formulated. Objectives The aim of this international study was to evaluate the predictive validity of the comprehensive (level II) version of these criteria by assessment of their contribution to the hazard of PD dementia. Methods Individual patient data were selected from four separate studies on cognition in PD that provided information on demographics, motor examination, depression, neuropsychological examination suitable for application of level II criteria, and longitudinal follow‐up for conversion to dementia. Survival analysis evaluated the predictive value of level II criteria for cognitive decline toward dementia as expressed by the relative hazard of dementia. Results A total of 467 patients were included. The analyses showed a clear contribution of impairment according to level II mild cognitive impairment criteria, age, and severity of PD motor symptoms to the hazard of dementia. There was a trend of increasing hazard of dementia with declining neuropsychological performance. Conclusions This is the first large international study evaluating the predictive validity of level II mild cognitive impairment criteria for PD. The results showed a clear and unique contribution of classification according to level II criteria to the hazard of PD dementia. This finding supports their predictive validity and shows that they contribute important new information on the hazard of dementia, beyond known demographic and PD‐specific factors of influence. © 2017 International Parkinson and Movement Disorder Society